New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 7, 2013
06:56 EDTACHNAchillion reports interim results on ACH-3102
Achillion announced that it has completed enrollment in a pilot Phase 2a trial evaluating ACH-3102, a second-generation pan-genotypic NS5A inhibitor, in combination with ribavirin for the treatment of patients with chronic genotype 1b hepatitis C virus infection. Up to 12 weeks of once daily ACH-3102 appears safe and well tolerated with no on-treatment virologic breakthrough observed to date.
News For ACHN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 15, 2014
13:06 EDTACHNAchillion December volatility elevated at 285
Achillion December call option implied volatility is at 285, January is at 231; compared to its 26-week average of 153 according to Track Data, suggesting large price movement.
05:58 EDTACHNStocks with implied volatility above IV index mean; ACHN DG
Subscribe for More Information
December 8, 2014
11:49 EDTACHNAchillion December volatility elevated
Subscribe for More Information
08:32 EDTACHNTrout Group to hold events at ASH 2014
Subscribe for More Information
06:12 EDTACHNStocks with implied volatility above IV index mean; LULU ACHN
Stocks with implied volatility above IV index mean; lululemon (LULU) 53, Achillion (ACHN) 216 according to iVolatility.
December 5, 2014
10:06 EDTACHNAchillion management to meet with JMP Securities
Subscribe for More Information
December 4, 2014
06:04 EDTACHNStocks with implied volatility above IV index mean; DG ACHN
Subscribe for More Information
December 3, 2014
06:02 EDTACHNStocks with implied volatility above IV index mean; DG ACHN
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use